Quanterix Wins 2025 R&D 100 Award for Simoa BD-Tau Advantage PLUS Assay

Quanterix has been named a winner of the 2025 R&D 100 Awards in the Analytical/Test category for the Simoa^® BD-Tau Advantage PLUS Assay. These prestigious awards, often referred to as the “Oscars of Innovation,” honor the 100 most impactful technologies worldwide that are shaping the future of science and industry.

The Simoa BD-Tau Advantage PLUS Assay enables the detection of brain-derived tau (BD-Tau) in blood, supporting research into earlier Alzheimer’s detection, more effective clinical trial design, and improved approaches to patient care.

Being recognized among global leaders in science and technology further validates the role of Quanterix’s ultrasensitive biomarker detection technology in driving innovation in precision health.

Read the full coverage on R&D World →